FinancialContent is the trusted provider of stock market information to the media industry.
March 09, 2012 at 14:27 PM EST
BioMimetic Therapeutics, Inc. to Report 2011 Fourth Quarter and Year-End Financial Results on March 13

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the twelve months ended December 31, 2011, on Tuesday, March 13, 2012, after market close. The Company will host a conference call and audio webcast to discuss its fourth quarter and year-end financial results, product development programs and business activities at 4:30 p.m. EDT the same day.

The conference call may be accessed on March 13, 2012 by dialing (877) 224 - 4059 for the U.S. and Canada (passcode: 57985649). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic received regulatory approval in 2009 and 2011 to market Augment in Canada, and in Australia for hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called Augmatrix Biocomposite Bone Graft.

For further information contact Kearstin Patterson, director of corporate communications, at 615-236-4419.

Contacts:

BioMimetic Therapeutics, Inc.
Corporate Communications:
Kearstin Patterson, 615-236-4419
mobile: 615-517-6112
kpatterson@biomimetics.com
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More